Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Pelthos Therapeutics, Inc.

Contributing Author

Recent Articles by Pelthos Therapeutics, Inc.

Aug-13
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results PTHS GlobeNewswire
Aug-03
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026 PTHS -6.35% GlobeNewswire
Jul-24
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders PTHS -8.73% PTHS +6.44% GlobeNewswire
Jun-30
Pelthos Therapeutics Added to Russell 3000E Growth Benchmark, Russell Microcap and Russell Microcap Growth Benchmark Indexes PTHS GlobeNewswire
May-28
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference PTHS GlobeNewswire
May-14
Pelthos Therapeutics Announces First Quarter 2026 Financial Results PTHS +6.46% GlobeNewswire
May-01
Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026 PTHS GlobeNewswire
Apr-14
Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium PTHS GlobeNewswire
Apr-10
Pelthos Therapeutics Announces CFO Transition PTHS GlobeNewswire
Mar-31
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain PTHS GlobeNewswire
Mar-19
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results PTHS GlobeNewswire
Mar-12
Pelthos Therapeutics to Present at 38th Annual ROTH Conference PTHS GlobeNewswire
Mar-09
Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 PTHS GlobeNewswire
Feb-23
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference PTHS +5.04% GlobeNewswire
Jan-13
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance PTHS GlobeNewswire
Jan-05
Pelthos Therapeutics Acquires Xeglyze (abametapir) Topical Treatment for Head Lice PTHS -9.03% GlobeNewswire
Dec-23
Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn PTHS GlobeNewswire
Dec-04
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI (berdazimer) Topical Gel, 10.3% PTHS GlobeNewswire
Dec-02
Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference PTHS GlobeNewswire
Nov-13
Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results PTHS -7.27% GlobeNewswire
Nov-07
Pelthos Therapeutics Acquires Xepi (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing PTHS -8.07% GlobeNewswire
Nov-05
Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025 PTHS +6.47% GlobeNewswire
Oct-09
Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum PTHS -7.89% GlobeNewswire
Sep-08
Pelthos Therapeutics to Participate in Upcoming September Investor Conferences PTHS +13.96% GlobeNewswire
Sep-02
Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference PTHS -5.03% GlobeNewswire
Aug-18
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update PTHS GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)